The seventh international RASopathies symposium: Pathways to a cure—expanding knowledge, enhancing research, and therapeutic discovery
Open Access
- 9 March 2022
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (6) , 1915-1927
Abstract
RASopathies are a group of genetic disorders that are caused by genes that affect the canonical Ras/mitogen‐activated protein kinase (MAPK) signaling pathway. Despite tremendous progress in understanding the molecular consequences of these genetic anomalies, little movement has been made in translating these findings to the clinic. This year, the seventh International RASopathies Symposium focused on expanding the research knowledge that we have gained over the years to enhance new discoveries in the field, ones that we hope can lead to effective therapeutic treatments. Indeed, for the first time, research efforts are finally being translated to the clinic, with compassionate use of Ras/MAPK pathway inhibitors for the treatment of RASopathies. This biannual meeting, organized by the RASopathies Network, brought together basic scientists, clinicians, clinician scientists, patients, advocates, and their families, as well as representatives from pharmaceutical companies and the National Institutes of Health. A history of RASopathy gene discovery, identification of new disease genes, and the latest research, both at the bench and in the clinic, were discussed.Keywords
Funding Information
- Children's Tumor Foundation
- Boehringer Ingelheim
- National Center for Advancing Translational Sciences
- National Institutes of Health (NIH‐R35 HL125742, NIH‐R01‐HL102368)
This publication has 51 references indexed in Scilit:
- The intermediate-activityL597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathwayGenes & Development, 2012
- Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome–associated PTPN11 mutationJournal of Clinical Investigation, 2011
- MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutationJournal of Clinical Investigation, 2011
- Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndromeNature, 2010
- Functional Effects of PTPN11 (SHP2) Mutations Causing LEOPARD Syndrome on Epidermal Growth Factor-Induced Phosphoinositide 3-Kinase/AKT/Glycogen Synthase Kinase 3β SignalingMolecular and Cellular Biology, 2010
- The Phosphatase SHP2 Regulates the Spacing Effect for Long-Term Memory InductionCell, 2009
- Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformationProceedings of the National Academy of Sciences, 2009
- Reduced phosphatase activity of SHP‐2 in LEOPARD syndrome: Consequences for PI3K binding on Gab1FEBS Letters, 2006
- Diversity and Functional Consequences of Germline and Somatic PTPN11 Mutations in Human DiseaseThe American Journal of Human Genetics, 2006
- Diverse Biochemical Properties of Shp2 MutantsJournal of Biological Chemistry, 2005